Matsuo K, et al. - In this study, survival after recurrence (SAR) was investigated among women with recurrent uterine carcinosarcoma who received a taxane/platinum doublet as the first-line salvage chemotherapy. Findings revealed that compared to other regimens, taxane/platinum doublet may be a more effective chemotherapy regimen among these women. This was particularly observed among those who had a disease-free interval of ≥ 6 months.

Methods

• A retrospective examination was performed of 148 women with recurrent uterine carcinosarcoma who received salvage chemotherapy within a cohort of 906 uterine carcinosarcomas.
• With multivariate analysis, researchers assessed an independent association of salvage chemotherapy type and SAR.

Results

• Researchers identified 71 (48.0%) women who received a taxane/platinum regimen.
• Univariate analysis suggested a higher 2-year SAR rate among women who received a taxane/platinum doublet compared to women who received non-taxane/platinum regimens (55.5% vs 34.8%, P < 0.001).
• Multivariate analysis suggested an independent association of use of taxane/platinum regimen with improved SAR compared to the non-taxane/platinum regimens (adjusted-hazard ratio [HR] 0.56, 95% confidence interval [CI] 0.35 to 0.91, P=0.02).
• Women with a disease-free interval ≥ 6 months receiving a taxane/platinum doublet indicated a higher 2-year SAR rate compared to those who received non-taxane/platinum regimens on stratification by disease-free interval (61.9% vs 40.0%, HR 0.46, 95% CI 0.28 to 0.75, P = 0.002); conversely, in women with a disease-free interval < 6 months, 2-year SAR rates were similar between the two groups (20.5% vs 18.4%, HR 0.80, 95% CI 0.33 to 1.90, P=0.61).
• Re-treatment with taxane/platinum doublet as salvage chemotherapy remained beneficial among women who received a taxane/platinum doublet as adjuvant chemotherapy (2-year SAR rate, 62.1% vs 39.7%, HR 0.40, 95% CI 0.18 to 0.86, P=0.019).